Skip to Main Content

Paper Details

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
J Immunother Cancer
12
2022
-expressing neuroblastoma cells, CAR, CAR T cell, CAR T cells, GPC2, GPC2-directed mRNA CAR T cells, GPC2-expressing medulloblastoma and high-grade glioma cell lines, GPC2-expressing neuroblastoma cells, Glypican 2, Pediatric brain tumors, RNA, brain tumor, brain tumors, cancer, cell lines, central nervous system, children, chimeric antigen receptor, embryonal tumors, gliomas, human, inflammatory neurotoxicity, mRNA, mRNA CAR T cell, mRNA CAR T cells, malignant pediatric brain tumors, medulloblastoma, medulloblastoma and high-grade glioma, medulloblastomas, multilayered rosettes, neuroblastoma, optimized mRNA, pediatric, pediatric brain tumors, primary pediatric, tumor
Author NameAffiliation
Jessica B FosterThe Children's Hospital of Philadelphia
Jessica B FosterCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Jessica B FosterUniversity of Pennsylvania Perelman School of Medicine
Crystal GriffinCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Jo Lynne RokitaCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Jo Lynne RokitaThe Children's Hospital of Philadelphia
Jo Lynne RokitaThe Children's Hospital of Philadelphia
Arnold SternCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Cameron BrimleyThe Children's Hospital of Philadelphia
Komal S RathiCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Komal S RathiThe Children's Hospital of Philadelphia
Komal S RathiCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Komal S RathiThe Children's Hospital of Philadelphia
Maria V LaneThe Children's Hospital of Philadelphia
Samantha N BuongervinoThe Children's Hospital of Philadelphia
Tiffany E Hill-SmithCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Peter J MadsenCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Peter J MadsenThe Children's Hospital of Philadelphia
Peter J MadsenCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Peter J MadsenThe Children's Hospital of Philadelphia
Daniel MartinezThe Children's Hospital of Philadelphia
Daniel MartinezThe Children's Hospital of Philadelphia
Alberto DelaidelliThe University of British Columbia
Poul H SorensenThe University of British Columbia
Poul H SorensenThe University of British Columbia
Robert J Wechsler-ReyaNCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Robert J Wechsler-ReyaNCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Katalin Karikó
Phillip B StormCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Phillip B StormUniversity of Pennsylvania Perelman School of Medicine
Phillip B StormThe Children's Hospital of Philadelphia
Phillip B StormCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Phillip B StormThe Children's Hospital of Philadelphia
Phillip B StormUniversity of Pennsylvania Perelman School of Medicine
David M Barrett
Adam C ResnickCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Adam C ResnickThe Children's Hospital of Philadelphia
Adam C ResnickCenter for Data-Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia
Adam C ResnickThe Children's Hospital of Philadelphia
John M MarisThe Children's Hospital of Philadelphia
John M MarisUniversity of Pennsylvania Perelman School of Medicine
John M MarisThe Children's Hospital of Philadelphia
John M MarisUniversity of Pennsylvania Perelman School of Medicine
Kristopher R BosseThe Children's Hospital of Philadelphia
Kristopher R BosseUniversity of Pennsylvania Perelman School of Medicine
  • 1 - 45

Datasets